http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
New England Journal of Medicine Publishes Phase 3 ASCENT-04/KEYNOTE-D19 Results Supporting Trodelvy® Plus Keytruda® as a Potential New Standard of Care in First-line PD-L1+ Metastatic Triple-negativ
-
Gilead Sciences acquires Repare drug candidate for up to $30 million
-
Gilead Sciences to Present at Upcoming Investor Conference
-
Gilead exercises option for Assembly Bio's herpes treatment programs
-
Gilead Sciences Exercises Option to License Assembly Biosciences’ Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes
-
GILEAD reaches three-year pricing agreement with US government
-
Gilead and U.S. Government Enter Agreement to Lower Costs of Medicines for Americans
-
Gilead Sciences names Keeley Wettan as executive vice president
-
Gilead Sciences Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance
-
Gilead Foundation Awards Over $3 Million to Support People Living With Metastatic Breast Cancer
-
Kite reports 96% response rate in multiple myeloma trial
-
Kite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel’s Opportunity in Relapsed or Refractory Multiple Myeloma
-
Gilead Foundation Commits Over $3 Million to Address Food Insecurity
-
Gilead ships first lenacapavir doses to sub-Saharan Africa
-
Gilead Joins Partners for Delivery of First Shipments of Breakthrough Twice-yearly Lenacapavir for HIV Prevention to Sub-Saharan Africa
-
Gilead's Trodelvy fails to meet primary endpoint in breast cancer study
-
Gilead Provides Update on Phase 3 ASCENT-07 Study
-
GILD presents long-term data on Livdelzi for liver disease treatment
-
Gilead’s Livdelzi® Demonstrates Sustained Efficacy in Primary Biliary Cholangitis (PBC), Offering Alkaline Phosphatase (ALP) Reduction, Itch Relief and Potential to Slow Disease Progression
-
Gilead Sciences to Present at Upcoming Investor Conferences
-
Gilead and Kite Showcase Continued Progress in Transforming Blood Cancer Care With New Cell Therapy Data at ASH 2025
-
Gilead Sciences Wins Prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product With Yeztugo® (Lenacapavir)
-
Gilead to present liver disease data at AASLD conference
-
Gilead to Showcase Interim Long-Term Efficacy Data for Livdelzi® (Seladelpar) in Primary Biliary Cholangitis (PBC) and Investigational Bulevirtide in Chronic Hepatitis Delta
-
Gilead to Spotlight New Virology Data Across HIV, Viral Hepatitis and Respiratory Diseases at IDWeek 2025
-
Trodelvy® Reduces Risk of Disease Progression or Death by 38% Versus Chemotherapy as First-Line Therapy in Patients With Metastatic Triple-Negative Breast Cancer in ASCENT-03 Study
-
Gilead to present Trodelvy breast cancer data at ESMO 2025
-
Gilead and Kite Reinforce Bold Commitment to Transform Cancer Care With New Data at ESMO 2025
-
Gilead Sciences to Release Third Quarter 2025 Financial Results on Thursday, October 30, 2025
-
Gilead Foundation Grants $6.5 Million in Commitment to STEM Education
-
Gilead partners with PEPFAR to deliver HIV prevention drug to 2 million people
-
Gilead Announces Partnership With PEPFAR to Deliver Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries
-
Gilead Sciences breaks ground on new manufacturing facility in Foster City
-
Gilead Sciences Breaks Ground on New Manufacturing Hub, a Cornerstone of Its U.S. Growth and Innovation Strategy
-
European Commission Authorizes Twice-Yearly Yeytuo® (Lenacapavir) for HIV Prevention
-
Gilead Sciences to Present at Upcoming Investor Conferences
-
Gilead receives positive EU opinion for twice-yearly HIV prevention drug
-
Gilead Receives Positive CHMP Opinions Under Accelerated Review From European Medicines Agency for Twice-Yearly Lenacapavir for HIV Prevention
-
Gilead Sciences to Release Second Quarter 2025 Financial Results on Thursday, August 7, 2025
-
Gilead presents data on twice-yearly HIV prevention drug at IAS 2025
-
Gilead Presents New Data on Twice-Yearly Lenacapavir (Yeztugo®) for HIV Prevention at IAS 2025
-
Gilead Finalizes Agreement With the Global Fund to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries
-
Gilead Sciences (GILD) and Kymera Therapeutics (KYMR) Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders
-
Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders
-
Gilead Sciences (GILD): Yeztugo Is Now the First and Only FDA-Approved HIV Prevention Option Offering 6 Months of Protection
-
Yeztugo® (Lenacapavir) Is Now the First and Only FDA-Approved HIV Prevention Option Offering 6 Months of Protection
-
Trodelvy® Plus Keytruda® Reduces Risk of Disease Progression or Death by 35% Versus Keytruda and Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer
-
Gilead Sciences (GILD) announces positive data from Phase 3 Trodelvy study
-
ASCENT-03: Trodelvy® Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement in Progression Free Survival in Patients With First-line Metastatic Triple-Negative Breast C
-
Gilead and Kite Announce Presentation of Transformative Data in 1L Metastatic Triple-Negative Breast Cancer, Updated Results in Multiple Myeloma and Early Data From Novel Investigational CAR T-Cell Th
